Differences Between Type I and Type II Papillary Renal Cell Carcinoma on Ultrasound

doi:10.37015/AUDT.2019.191220

Abstract

Abstract:

Objective: To identify the characteristics and differences between type I and type II papillary renal cell carcinoma (PRCC) using ultrasound.
Methods: Twenty-five patients with PRCC, including 16 cases of type I and 9 cases of type II PRCC, were enrolled in this study. All lesions were surgically resected and pathologically confirmed. A conventional ultrasound and a contrast-enhanced ultrasound were performed on each of the 25 patients with PRCC before the operation. Both ultrasounds were performed by a single highlyqualified doctor with more than 10 years of experience. Features, including maximum diameter, boundary, shape, and growth pattern of the mass, color Doppler flow image (CDFI), enhancement pattern, degree, and uniformity, arrival time; and time to peak, obtained from the conventional and contrast-enhanced ultrasounds, were analyzed and compared between type I and type II PRCC.
Results: On conventional ultrasound, type II PRCCs were significantly larger (P = 0.000), less clear (P = 0.001) and more irregular (P = 0.004) than type I PRCCs. There was also a statistically significant difference in growth pattern (P = 0.019) and enhancement uniformity (P = 0.016) between type I and II PRCC.
Conclusion: There are statistically significant differences in sonographic features between the two types of PRCC. This knowledge could assist clinicians when choosing surgical procedures.

Key words: Papillary renal cell carcinoma; Pathology; Ultrasound; Contrast-enhanced ultrasound

Qing Zhang, MD, Shuping Wei, MD, Bin Yang, MD, Xiaoqin Qian, MD. Differences Between Type I and Type II Papillary Renal Cell Carcinoma on Ultrasound. Advanced Ultrasound in Diagnosis and Therapy, 2019, 3(4): 187-192.

References

[1]	Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, et al. Kidney cancer. J Natl Compr Canc Netw 2011; 9:960-77.
[2]	Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2016; 70:93-105.
[3]	Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol 2016; 8:484-500.
[4]	Scelo G, Larose TL. Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol 2018: JCO2018791905.
[5]	Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(suppl 5):v58-v68.
[6]	Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nols?e CP, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39:187-210.
[7]	Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications:Retrospective analysis of 23188 investigations. Ultrasound in Medicine & Biology. 2006; 32:1369-75.
[8]	Piscaglia F, Bolondi L; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32:1369-75.
[9]	Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A. Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virchows Arch 2003; 442:336-42.
[10]	Harvey CJ, Alsafi A, Kuzmich S, Ngo A, Papadopoulou I, Lakhani A, et al. Role of US Contrast Agents in the Assessment of Indeterminate Solid and Cystic Lesions in Native and Transplant Kidneys. Radiographics 2015; 35:1419-30.
[11]	Piscaglia F, Nols?e C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2012; 33(1):33-59.
[12]	Sun D, Wei C, Li Y, Lu Q, Zhang W, Hu B. Contrast-Enhanced Ultrasonography with Quantitative Analysis allows Differentiation of Renal Tumor Histotypes. Sci Rep 2016; 6:35081.
[13]	Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, et al. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma. AJR Am J Roentgenol 2017; 208:812-819.
[14]	Mueller-Peltzer K, Negrao de Figueiredo G, Graf T, Rübenthaler J, Clevert DA. Papillary renal cell carcinoma in contrast-enhanced ultrasound (CEUS) - A diagnostic performance study. Clin Hemorheol Microcirc 2019; 71:159-164.
[15]	Gonnet A, Salabert L, Roubaud G, Catena V, Brouste V, Buy X, et al. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer 2019; 19:1182.
[16]	Kosaka T, Mikami S, Miyajima A, Kikuchi E, Nakagawa K, Ohigashi T, et al. Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients. Clin Exp Nephrol 2008; 12:195-9.
[17]	Thoenes W, St?rkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181:125-43.
[18]	Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10:537-44.
[19]	Yamashita S, Ioritani N, Oikawa K, Aizawa M, Endoh M, Arai Y. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis. Int J Urol 2007; 14:679-83.
[20]	Egbert ND, Caoili EM, Cohan RH, Davenport MS, Francis IR, Kunju LP, et al. Differentiation of papillary renal cell carcinoma subtypes on CT and MRI. AJR Am J Roentgenol 2013; 201:347-55.
[21]	Yamada T, Endo M, Tsuboi M, Matsuhashi T, Takase K, Higano S, et al. Differentiation of pathologic subtypes of papillary renal cell carcinoma on CT. AJR Am J Roentgenol 2008; 191:1559-63.
[22]	Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Str?bel P, Radzun HJ. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch 2014; 464:191-6.
[23]	Kopp RP, Aganovic L, Palazzi KL, Cassidy FH, Sakamoto K, Derweesh IH. Differentiation of clear from non-clear cell renal cell carcinoma using CT washout formula. Can J Urol 2013; 20:6790-7.